. Author manuscript; available in PMC: 2020 Jul 30.

Published in final edited form as: Bioorg Med Chem Lett. 2018 Aug 31;28(21):3483–3488. doi: 10.1016/j.bmcl.2018.08.039

Table 5.

The PK profiles of selected analogs in CD-1 mice.

Cpd.	administration^a	t_1/2 (h)	C_max (ng/mL)^b	AUC_0−∞ (h●ng/mL)	V_ss (L/kg)	CL_p (mL/min/kg)	F%
34	po (10 mg/kg)^c	4.0	9	54
48	po (10 mg/kg)^d			BLOQ^e
65	iv (2 mg/kg)^f	3.1	1690	1757	1.7	19.8
65	po (10 mg/kg)^f	2.1	934	4494			51

n= 3, iv and po represents intravenous and oral administration, respectively.

The maximum drug concentration (Cmax) was observed at t = 5 min, the first sampling time point after iv administration.

The compound was formulated as a solution in PEG400/water (1/3).

The compound was formulated as a solution in 20% HP-β-CD in water.

BLOQ: below limit of quantitation.

The compound was formulated as a solution in 30% solutol in water and adjusted pH with 1.05 equiv of HCl using 0.1 N HCl_(aq).